Post-ASCT consolidation with elotuzumab, lenalidomide, and dexamethasone or elotuzumab, pomalidomide, and dexamethasone in high-risk and ultra-high-risk multiple myeloma: a retrospective single-center study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Post-ASCT consolidation with elotuzumab, lenalidomide, and dexamethasone or elotuzumab, pomalidomide, and dexamethasone in high-risk and ultra-high-risk multiple myeloma: a retrospective single-center study

Published:2024-07-31 Issue: Volume: Page:1-9
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Zolotov Eli¹^ORCID,Kabat Maciej¹,Parmar Harsh²,Anand Palka²,Zenreich Joshua²,Aleman Adolfo²,Phull Pooja²,Doucette Kimberly³,Vesole David H.²,Siegel David S.²,Biran Noa²

Affiliation:

1. Department of Internal Medicine, Hackensack University Medical Center, Hackensack, NJ, USA

2. John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

3. MedStar Georgetown University Hospital, Lombardi Cancer Center, Washington, DC, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2385501

Reference21 articles.

1. Cancer statistics, 2024

2. Myeloma – cancer stat facts. SEER; n.d. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html

3. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

4. Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial

5. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP